Formex, LLC, a provider of small molecule formulation and clinical trial manufacturing, has launched its dedicated suites for R&D and cGMP production capabilities of cytotoxic and potent pharmaceuticals.
 
“The addition of our cytotoxic and potent handling suites deepens Formex’s ability to handle a broader range of active pharmaceutical ingredients (APIs). Specialized handling of cytotoxic and potent compounds is a strategic complement to our existing technologies for bioavailability enhancement and controlled release technologies,” said Rudy J. Emmelot, president and chief executive officer of Formex. “Formex is very proud of its 80,000 sq.-ft. facility in Torrey Pines, CA, and we look forward to continually expanding within our facility to offer more capabilities and dedicated services in formulation and cGMP manufacturing to our clients within the biotech, pharmaceutical, and healthcare industries.”
 
Formex has more than 25,000 sq.-ft. of cGMP clinical and commercial manufacturing space, including 17 dedicated cGMP suites. The company has suites qualified and dedicated for cytotoxic and potent compound handling. The Formex facility has more than 40,000 sq.-ft. dedicated to R&D, analytical labs, and cGMP ICH stability storage with temperature controlled cGMP warehouses.